Literature DB >> 16154574

Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration.

Bo Zhang1, Ping Fan, Eiso Shimoji, Hiroyuki Itabe, Shin-ichiro Miura, Yoshinari Uehara, Akira Matsunaga, Keijiro Saku.   

Abstract

BACKGROUND: Platelet-activating factor acetylhydrolyse (PAF-AH) is an enzyme that degrades PAF and bioactive oxidized lipids. However, it has been reported to be a risk factor for coronary heart disease. The present study examined the effects of cholesterol feeding and simvastatin treatment on plasma PAF-AH activity.
METHODS: Japanese White rabbits (n=22) were fed a diet containing 0.3% cholesterol and 3% corn oil for 1 month, and then divided into two groups that continued to receive this diet with (treated) or without (control) treatment with simvastatin (0.01%) for another 2 months.
RESULTS: Cholesterol feeding increased and simvastatin treatment decreased apolipoprotein (apo) B-containing lipoprotein subfractions as characterized by capillary isotachophoresis, serum levels of total cholesterol, phospholipids, LDL-C, apoE, plasma and LDL-associated PAF-AH (LDL-PAF-AH) activities, and plasma lyso-PC concentration. Cholesterol feeding also increased apoB levels but decreased the LDL-PAF-AH/LDL-C ratio and did not change the plasma PAF-AH/lyso-PC ratio. Simvastatin treatment did not affect apoB levels and only slightly increased the LDL-PAF-AH/LDL-C ratio. Secretion of PAF-AH activity from monocyte-derived macrophages was increased by cholesterol feeding but not affected by simvastatin treatment. These results indicate that PAF-AH activity is increased by cholesterol feeding due to increased secretion of PAF-AH activity from macrophages and that PAF-AH activity is decreased by simvastatin due to increased removal of lipid and enzyme contents of LDL particles.
CONCLUSION: Cholesterol elevation by cholesterol feeding and cholesterol-lowering by simvastatin modulate plasma PAF-AH activity by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16154574     DOI: 10.1016/j.atherosclerosis.2005.07.029

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids.

Authors:  Jaewoo Choi; Wujuan Zhang; Xiaodong Gu; Xi Chen; Li Hong; James M Laird; Robert G Salomon
Journal:  Chem Res Toxicol       Date:  2010-10-25       Impact factor: 3.739

2.  Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study.

Authors:  Bo Zhang; Akira Matsunaga; David L Rainwater; Shin-Ichiro Miura; Keita Noda; Hiroaki Nishikawa; Yoshinari Uehara; Kazuyuki Shirai; Masahiro Ogawa; Keijiro Saku
Journal:  J Lipid Res       Date:  2008-12-03       Impact factor: 5.922

3.  Lysophosphatidylcholine acyltransferase 3 knockdown-mediated liver lysophosphatidylcholine accumulation promotes very low density lipoprotein production by enhancing microsomal triglyceride transfer protein expression.

Authors:  Zhiqiang Li; Tingbo Ding; Xiaoyue Pan; Yan Li; Ruohan Li; Philip E Sanders; Ming-Shang Kuo; M Mahmood Hussain; Guoqing Cao; Xian-Cheng Jiang
Journal:  J Biol Chem       Date:  2012-04-17       Impact factor: 5.157

4.  Carboxyethylpyrroles: From Hypothesis to the Discovery of Biologically Active Natural Products.

Authors:  Robert G Salomon
Journal:  Chem Res Toxicol       Date:  2016-11-02       Impact factor: 3.739

5.  The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.

Authors:  Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis
Journal:  J Lipid Res       Date:  2013-10-03       Impact factor: 5.922

6.  A MALDI MS investigation of the lysophosphatidylcholine/phosphatidylcholine ratio in human spermatozoa and erythrocytes as a useful fertility marker.

Authors:  Ariane Nimptsch; Susanne Pyttel; Uwe Paasch; Christoph Mohr; Jan-Michael Heinrich; Jürgen Schiller
Journal:  Lipids       Date:  2013-12-04       Impact factor: 1.880

Review 7.  Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review.

Authors:  Isis T Silva; Ana P Q Mello; Nágila R T Damasceno
Journal:  Lipids Health Dis       Date:  2011-09-28       Impact factor: 3.876

8.  Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.

Authors:  Ngoc-Anh Le; Joanne E Tomassini; Andrew M Tershakovec; David R Neff; Peter W F Wilson
Journal:  J Am Heart Assoc       Date:  2015-10-20       Impact factor: 5.501

9.  Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.

Authors:  Boris Perelman; Areej Adil; Peter Vadas
Journal:  Allergy Asthma Clin Immunol       Date:  2014-04-28       Impact factor: 3.406

10.  Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism.

Authors:  Samuel Hernandez-Anzaldo; Vesna Brglez; Bianca Hemmeryckx; Dickson Leung; Janos G Filep; Jean E Vance; Dennis E Vance; Zamaneh Kassiri; Roger H Lijnen; Gérard Lambeau; Carlos Fernandez-Patron
Journal:  J Am Heart Assoc       Date:  2016-09-30       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.